Observational studyInternational urogynecology journal2025
Five-Year Follow-up Study on Safety and Efficacy of Macroplastique® in Female Patients with Stress Urinary Incontinence (the ROSE Study).
Observational study in International urogynecology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisThis study presents the 5-year study close-out results from the Real-Time Observation of Safety and Effectiveness (ROSE) study, evaluating the safety and efficacy of the Macroplastique® (MPQ) urethral bulking agent for the treatment of stress urinary incontinence (SUI) in women with intrinsic sphincter deficiency (ISD).
methodsThe ROSE study was an observational prospective study conducted at 22 US centers that enrolled 274 adult women with ISD-confirmed SUI. Participants underwent MPQ treatment with an option for repeat injections. Follow-up assessments were conducted at 3 months and then annually for 5 years, evaluating SUI severity (Stamey grade), Incontinence Quality of Life (I-QoL), and Patient Global Impression of Satisfaction. Safety outcomes included treatment-related adverse events (AEs) and serious adverse events (SAEs).
resultsOf 274 enrolled participants, 147 (54%) completed the 5-year follow-up. At 5 years, 47.6% 19 (70/147) of women showed improvement in SUI severity as measured by Stamey grade from 20 baseline after their last injection. I-QoL scores improved significantly, from 45 ± 23.9 to 70.9 ± 21 24.5 (1.1, 100). One device-related SAE of urinary retention (0.4%) resolved within 4 months; no 22 late-onset SAEs were reported. The most common minor treatment-related adverse events were 23 urinary tract infections (30.8%) and transient urinary retentions (7.2%). No late-onset SAEs were 24 reported during the 5-year period.
conclusionsMacroplastique® demonstrated sustained long-term efficacy and safety in managing SUI owing to 27 ISD. These findings reinforce its role as a minimally invasive treatment option with 28 durable outcomes over 5 years.
Indexed as
Identifiers
40504248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.